Aduro Biotech, which is developing an immunotherapy for pancreatic cancer, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
2014 immuno-oncology biotech IPOs have traded well, including Kite Pharma (KITE; +287%), Immune Design (IMDZ; +114%) and Juno Therapeutics (JUNO; +108%).
The Berkeley, CA-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol ADRO. Aduro Biotech initially filed confidentially on December 19, 2014. BofA Merrill Lynch and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
